Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and...

Area of Science:

• Oncology
• Genomics
• Pharmacology

Background:

• Lung cancer, particularly non-small cell lung cancer (NSCLC), accounts for a significant portion of cancer-related mortality.
• Despite advancements in targeted therapy and immunotherapy, challenges like drug resistance and low survival rates persist in advanced NSCLC.
• Comprehensive genomic profiling has revolutionized NSCLC classification, enabling personalized treatment strategies based on genetic features and PD-L1 expression.

Purpose of the Study:

• To review current therapeutic strategies for advanced-stage NSCLC.
• To focus on the development and application of targeted therapy and immunotherapy in NSCLC.
• To provide an updated summary of standard NSCLC treatments based on recent guidelines and discuss emerging therapies.

Main Methods:

• Literature review of recent therapeutic strategies for advanced-stage NSCLC.
• Analysis of the role of targeted therapy and immunotherapy based on genetic profiling and PD-L1 expression.
• Synthesis of information from the latest clinical guidelines and research on potential novel therapies.

Main Results:

• Over 10 new therapeutic strategies have been approved for specific NSCLC subgroups in the last two years.
• Treatment decisions for advanced NSCLC are increasingly guided by molecular profiling and PD-L1 status.
• Despite progress, challenges in overcoming drug resistance and improving overall survival remain critical areas for research.

Conclusions:

• Targeted therapy and immunotherapy represent significant advancements in treating advanced NSCLC.
• Personalized medicine approaches, driven by genomic profiling, are transforming NSCLC management.
• Future directions include the development of novel drugs and combination therapies to enhance treatment efficacy and patient outcomes in NSCLC.